Authors: Gordon, A.C.; Mouncey, P.R.; Al-Beidh, F.; Rowan, K.M.; Nichol, A.D.; Arabi, Y.M.; Annane, D.; Beane, A.; van Bentum-Puijk, W.; Berry, L.R.; Bhimani, Z.; Bonten, M.J.M.; Bradbury, C.A.; Brunkhorst, F.M.; Buzgau, A.; Cheng, A.C.; Detry, M.A.; Duffy, E.J.; Estcourt, L.J.; Fitzgerald, M.; Goossens, H.; Haniffa, R.; Higgins, A.M.; Hills, T.E.; Horvat, C.M.; Lamontagne, F.; Lawler, P.R.; Leavis, H.L.; Linstrum, K.M.; Litton, E.; Lorenzi, E.; Marshall, J.C.; Mayr, F.B.; McAuley, D.F.; McGlothlin, A.; McGuinness, S.P.; McVerry, B.J.; Montgomery, S.K.; Morpeth, S.C.; Murthy, S.; Orr, K.; Parke, R.L.; Parker, J.C.; Patanwala, A.E.; Pettilä, V.; Rademaker, E.; Santos, M.S.; Saunders, C.T.; Seymour, C.W.; Shankar-Hari, M.; Sligl, W.I.; Turgeon, A.F.; Turner, A.M.; van de Veerdonk, F.L.; Zarychanski, R.; Green, C.; Lewis, R.J.; Angus, D.C.; McArthur, C.J.; Berry, S.; Schouten, J.A.; Pickkers, P.; Webb, S.A.; Derde, L.P.G.

Venue: New England Journal of Medicine

Type: Publication

Abstract: BACKGROUND: The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. METHODS: We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24 hours after starting organ support in the intensive care unit (ICU), were randomly assigned to receive tocilizumab (8 mg per kilogram of body weight), sarilumab (400 mg), or standard care (control). The primary outcome was respiratory and cardiovasc... (read more)

Impact:   1.8572837E-6    1.0302559E-7    1877    1868  / Attention: 0 27

DOI: 10.1056/nejmoa2100433